Dissecting endometrial cancer complexity in response to standard and targeted therapies

Endometrial cancer (EC) is one of the most common gynecologic malignancies amongst women worldwide. Its incidence and mortality rates have been increasing in the last decade. In the present work, we built a patient EC-derived organoid (PDOs) platform that faithfully recapitulated tumor phenotype, genomic alterations, and expression profiles of matched-primary cancer tissues. Interestingly, we found that the response of EC-derived PDOs to both standard therapy and a wide range of targeted drugs accordingly to their specific druggable genetic alterations was congruent with that of the originating patients. We also isolated and genomically characterized matched-PDO stromal cells, specifically cancer-associated fibroblasts (CAFs). Unlike PDOs matched CAFs were poorly responsive and underwent to pro-inflammatory senescence upon treatment with standard therapy. Collectively, our findings established a EC-PDOs preclinical platform which allows assessing the therapeutic response of tumor and surrounding tumor microenvironment cellular landscape.

Authors

Institutions

Publication Details

Journal
Cell Death and Disease
Published
2025-11-28
DOI
https://doi.org/10.1038/s41419-025-08051-8
Citations
2
Primary Topic
Cancer Cells and Metastasis
Type
article
Field-Weighted Citation Impact
2.09
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Dissecting endometrial cancer complexity in response to standard and targeted therapies

Yaron Vinik, Sabrina Strano, Antonello Vidiri, Ludovica Ciuffreda et al.
2 citations
Cell Death and Disease
Cancer Cells and Metastasis
2.09
article

Dissecting endometrial cancer complexity in response to standard and targeted therapies

Yaron Vinik, Sabrina Strano, Antonello Vidiri, Ludovica Ciuffreda, Matteo Allegretti, Daniela Angela Covino, Carlotta Frascolla, Enrico Vizza, Simona Di Martino, Valentina Bruno, Valentina De Pascale, Mariantonia Carosi, Frauke Goeman, Sara Donzelli, Ermelinda Baiocco, Riccardo Vizza, Giovanni Blandino, Sima Lev, Giulia Orlandi, Maurizio Fanciulli, Emanuela Mancini, Andrea Sacconi, Claudio Pulito, G Urbani, Anna Bagnato, Sebastiano Vaccarella, Brindusa Ana Maria Arteni, Ramy Kajal
article en
2 citations

Abstract

Endometrial cancer (EC) is one of the most common gynecologic malignancies amongst women worldwide. Its incidence and mortality rates have been increasing in the last decade. In the present work, we built a patient EC-derived organoid (PDOs) platform that faithfully recapitulated tumor phenotype, genomic alterations, and expression profiles of matched-primary cancer tissues. Interestingly, we found that the response of EC-derived PDOs to both standard therapy and a wide range of targeted drugs accordingly to their specific druggable genetic alterations was congruent with that of the originating patients. We also isolated and genomically characterized matched-PDO stromal cells, specifically cancer-associated fibroblasts (CAFs). Unlike PDOs matched CAFs were poorly responsive and underwent to pro-inflammatory senescence upon treatment with standard therapy. Collectively, our findings established a EC-PDOs preclinical platform which allows assessing the therapeutic response of tumor and surrounding tumor microenvironment cellular landscape.

Cell Death and DiseaseVol. 16(1)
National Cancer Institute (MY), Istituti Fisioterapici Ospitalieri (IT), San Gallicano Hospital (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Weizmann Institute of Science (IL)
Openalex Percentile: Top 10%
Cancer Cells and Metastasis
2.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.